Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Leonard P. James"'
Autor:
Joseph Chen, Ana Ruiz‐Garcia, Leonard P. James, Gerson Peltz, Holger Thurm, Jill Clancy, Jennifer Hibma
Publikováno v:
Clinical Pharmacology & Therapeutics. 111:1197-1198
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8bf3d46d58abbef462f34ae1969cd985
https://doi.org/10.1002/cpt.2580
https://doi.org/10.1002/cpt.2580
Autor:
Kimberly C. Lee, Gerson Peltz, Michelle Bergeron, Leonard P. James, Sylvester Pawlak, Yazdi K. Pithavala, Katherine Ginman, Huiping Xu, Joseph Chen
Publikováno v:
Advances in Therapy. 37:745-758
Lorlatinib is a third-generation tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer; cytochrome P450 (CYP) 3A plays an important role in the metabolism of lorlatinib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17bdfcfebdd297ad7b1036a9b7d32bb0
https://doi.org/10.1007/s12325-019-01198-9
https://doi.org/10.1007/s12325-019-01198-9
Autor:
Joseph Chen, Gerson Peltz, Ana Ruiz-Garcia, Jennifer E. Hibma, Jill S. Clancy, Holger Thurm, Leonard P. James
Publikováno v:
Clinical pharmacology and therapeutics. 110(5)
Lorlatinib is a small molecule inhibitor of anaplastic lymphoma kinase (ALK) and c-ROS oncogene 1 (ROS1) tyrosine kinases and is approved for the treatment of patients with ALK-positive advanced non-small cell lung cancer (NSCLC). In the phase I/II s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::362ddfb16a7fc509881c380dc505a397
https://pubmed.ncbi.nlm.nih.gov/35394660
https://pubmed.ncbi.nlm.nih.gov/35394660
Autor:
Takashi Seto, Alice T. Shaw, Shirish M. Gadgeel, Benjamin Besse, Chia-Chi Lin, Sai-Hong Ignatius Ou, Jill S. Clancy, Joseph Chen, Gregory J. Riely, Eng Huat Tan, Holger Thurm, Todd M. Bauer, Gerson Peltz, D. Ross Camidge, Leonard P. James, Rita Chiari, Alessandra Bearz, Benjamin Solomon, Enriqueta Felip, Ross A. Soo, Antonello Abbattista, Jean-Francois Martini
Publikováno v:
The Lancet Oncology. 19:1654-1667
Summary Background Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of ALK and ROS1 tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study, activity was seen in patients with ALK-positive non-small-cell lung canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30124db84ef40bde8436e51228a5807a
https://doi.org/10.1016/s1470-2045(18)30649-1
https://doi.org/10.1016/s1470-2045(18)30649-1
Autor:
Justin F. Gainor, Alice T. Shaw, Jill S. Clancy, Melissa Lynne Johnson, Sophie Postel-Vinay, Benjamin Solomon, Enriqueta Felip, Leonard P. James, Joseph Chen, Benjamin Besse, Alejandro Navarro, Todd M. Bauer, Jorg Dietrich, Antonello Abbattista, Jean-Francois Martini
Publikováno v:
The Lancet. Oncology
Summary Background Most patients with anaplastic lymphoma kinase ( ALK )-rearranged or ROS proto-oncogene 1 ( ROS1 )-rearranged non-small-cell lung cancer (NSCLC) are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably dev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5d310de90512d3b2487834f4a2e8462
http://europepmc.org/articles/PMC5777233
http://europepmc.org/articles/PMC5777233
Autor:
Zelanna Goldberg, D. Ross Camidge, Benjamin Solomon, Jean-Francois Martini, S. Martin Shreeve, Yiyun Tang, Huiping Xu, Alice T. Shaw, Pasi A. Jänne, Leonard P. James, Giuseppe Giaccone
Publikováno v:
Journal of Thoracic Oncology. 11:737-747
Introduction This phase I study investigated the activity of the irreversible pan-human epidermal growth factor receptor inhibitor dacomitinib in combination with the mesenchymal-epithelial transition factor/anaplastic lymphoma kinase/ROS proto-oncog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::742445eaf0894d3055c8d27db7c36df2
https://doi.org/10.1016/j.jtho.2016.01.022
https://doi.org/10.1016/j.jtho.2016.01.022
Autor:
Joseph Chen, Huiping Xu, Sylvester Pawlak, Leonard P. James, Gerson Peltz, Kimberly Lee, Katherine Ginman, Michelle Bergeron, Yazdi K. Pithavala
Publikováno v:
Advances in Therapy. 37:4754-4754
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1747b3bf551e27d543b3273173a092ac
https://doi.org/10.1007/s12325-020-01480-1
https://doi.org/10.1007/s12325-020-01480-1
Autor:
S. Gadgeel, Todd M. Bauer, Ross A. Soo, S-H.I. Ou, Leonard P. James, Benjamin Besse, Takashi Seto, E. Felip Font, Antonello Abbattista, Jill S. Clancy, Ben Solomon, Alice T. Shaw
Publikováno v:
Annals of Oncology. 28:v478-v479
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8245319a60809844215c810416c5c44f
https://doi.org/10.1093/annonc/mdx380.045
https://doi.org/10.1093/annonc/mdx380.045
Autor:
E. Felip Font, Antonello Abbattista, C-C. Lin, Todd M. Bauer, Miyako Satouchi, Alice T. Shaw, Ben Solomon, Benjamin Besse, Leonard P. James, Rita Chiari, Jill S. Clancy
Publikováno v:
Annals of Oncology. 28:v465-v466
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f10931c7809e6e1ac84fd4dda900ad7
https://doi.org/10.1093/annonc/mdx380.011
https://doi.org/10.1093/annonc/mdx380.011
Autor:
Todd M. Bauer, Karen J. Klamerus, Benjamin Besse, J.-F. Martini, Jill S. Clancy, Benjamin Solomon, Enriqueta Felip, Alice T. Shaw, Leonard P. James, Antonello Abbattista
Publikováno v:
Journal of Thoracic Oncology. 12:S383-S384
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b69ae17195240317845e55a366118fe
https://doi.org/10.1016/j.jtho.2016.11.433
https://doi.org/10.1016/j.jtho.2016.11.433